CD20: A review

被引：0
|
作者：
Chang, KL
Arber, DA
Weiss, LM
机构：
来源：
APPLIED IMMUNOHISTOCHEMISTRY | 1996年 / 4卷 / 01期
关键词：
CD20; immunohistochemistry; mature B-cells; B-cell lymphoma; B-cell ontogeny; REED-STERNBERG CELLS; HUMAN LYMPHOCYTE-B; PARAFFIN SECTION IMMUNOHISTOCHEMISTRY; NON-HODGKINS LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MONOCLONAL-ANTIBODIES; BONE-MARROW; DIFFERENTIATION ANTIGEN; PREDOMINANCE TYPE; EPITHELIAL-CELLS;
D O I：
暂无
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
CD20 is a membrane-embedded 35-37 kDa nonglycosylated phosphoprotein that is a restricted B-cell antigen. CD20 antibodies are available for paraffin and frozen section immunohistochemistry and for flow cytometric analysis. Its clinical utility is greatest for identifying B-lineage non-Hodgkin's lymphomas, but it can also aid in the diagnosis of nodular lymphocyte predominance Hodgkin's disease and acute lymphoblastic neoplasms. CD20 immunotoxins have also been used experimentally to treat B-cell lymphomas that do not respond to conventional chemotherapy or radiation therapy.
引用
收藏
页码：1 / 15
页数：15
相关论文
共 50 条
  • [31] Complementing CD20 antibodies' effector functions
    Leusen, Jeanette
    Valerius, Thomas
    BLOOD, 2025, 145 (12) : 1232 - 1234
  • [32] CD20 as a target for therapy in solid tumors
    Affara, Nesrine I.
    Ruffell, Brian
    Johansson, Magnus
    Fujikawa, Kerri
    Bergsland, Emily
    DeNardo, David G.
    Chen, Heather I.
    Wadhwani, Nikhil
    Steinhoff, Martin
    Truitt, Morgan
    Olson, Peter
    Hanahan, Douglas
    Li, Yijin
    Gong, Qian
    Ma, Yan
    Wiesen, Jane F.
    Kim, Grace
    Tempero, Margaret
    Balkwill, Frances
    Irving, Bryan
    Coussens, Lisa M.
    CANCER RESEARCH, 2012, 72
  • [33] CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20(+), surface CD20(-)
    Yokose, Norio
    Shioi, Yumiko
    Sugisaki, Yuich
    Ohaki, Yoshiharu
    Ogata, Kiyoyuki
    Dan, Kazuo
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1415 - 1417
  • [34] CD20 antibodies: type II to tango?
    van Oers, Marinus H. J.
    BLOOD, 2012, 119 (22) : 5061 - 5063
  • [35] Targeting CD20 takes the backseat in CLL
    Byrd, John C.
    BLOOD, 2019, 133 (10) : 1003 - 1004
  • [36] THE EFFECT OF PRONASE ON HLA AND CD20 ANTIGENS
    Stevens, Ryan D.
    Darke, Christopher
    TISSUE ANTIGENS, 2013, 81 (05): : 339 - 339
  • [37] Rituximab in CD20 positive multiple myeloma
    Moreau, P.
    Voillat, L.
    Benboukher, L.
    Mathiot, C.
    Dumontet, C.
    Robillard, N.
    Herault, O.
    Garnache, F.
    Garand, R.
    Varoqueaux, N.
    Avet-Loiseau, H.
    Harousseau, J. L.
    Bataille, R.
    LEUKEMIA, 2007, 21 (04) : 835 - +
  • [38] A Case of Cd20 Positive Mediastinal Rhabdomyosarcoma
    Diniz, Gulden
    Genel, Ferah
    Yucel, Nur
    Turedi, Aysen
    Vergin, Canan
    TURKISH JOURNAL OF PATHOLOGY, 2012, 28 (03) : 270 - 273
  • [39] Transient downmodulation of CD20 by rituximab.
    Jilani, I
    O'Brien, S
    Manshouri, T
    Thomas, DA
    Thomazy, VA
    Imam, M
    Naeem, S
    Verstovsek, S
    Kantarjian, H
    Giles, F
    Keating, M
    Albitar, M
    BLOOD, 2002, 100 (11) : 804A - 804A
  • [40] Inhibitory FcγRIIb and CD20 internalization
    Dransfield, Ian
    BLOOD, 2014, 123 (05) : 606 - 607
12345